X4 PHARMACEUTICALS INC (XFOR) — insider trading
Health Care · NASDAQ
X4 PHARMACEUTICALS INC (XFOR) has 14 reported SEC Form 4 insider transactions in our data, including 1 open-market purchase and 5 open-market sales among the most recent 14 (latest 2026-10-01).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | KIRSKE DAVID | Officer (Chief Financial Officer) | Open-market sale | 11,767 | $2.86 | $33.7K | Form 4 |
| 2026-08-12 | Craig Adam R | Director, Officer (Executive Chairman) | Open-market sale | 47,436 | $4.44 | $210.8K | Form 4 |
| 2026-08-12 | Volpone John | Officer (President) | Open-market sale | 24,576 | $4.44 | $109.2K | Form 4 |
| 2026-07-01 | Gold Kelly | Director | Grant / award / vesting (derivative) | 110,000 | — | $0 | Form 4 |
| 2026-06-30 | KIRSKE DAVID | Officer (Chief Financial Officer) | Open-market sale | 8,543 | $4.26 | $36.4K | Form 4 |
| 2026-05-12 | KIRSKE DAVID | Officer (Chief Financial Officer) | Open-market sale | 16,961 | $4.29 | $72.8K | Form 4 |
| 2026-01-01 | Bridger Gary | Director | Grant / award / vesting (derivative) | 110,000 | — | $0 | Form 4 |
| 2026-01-01 | Stewart Murray | Director | Grant / award / vesting (derivative) | 110,000 | — | $0 | Form 4 |
| 2026-01-01 | WYZGA MICHAEL S | Director | Grant / award / vesting (derivative) | 110,000 | — | $0 | Form 4 |
| 2026-01-01 | de Craecker Francoise | Director | Grant / award / vesting (derivative) | 110,000 | — | $0 | Form 4 |
| 2025-10-29 | KIRSKE DAVID | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 1,552,769 | — | $0 | Form 4 |
| 2025-10-29 | Volpone John | Officer (President) | Grant / award / vesting (derivative) | 2,329,154 | — | $0 | Form 4 |
| 2025-10-29 | Craig Adam R | Director, Officer (Executive Chairman) | Grant / award / vesting (derivative) | 2,329,154 | — | $0 | Form 4 |
| 2025-10-23 | Craig Adam R | Director, Officer (Executive Chairman) | Open-market purchase | 86,206 | $2.90 | $250.0K | Form 4 |
Ask the chat about XFOR's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: X4 PHARMACEUTICALS INC (XFOR).
Last updated 2026-10-01 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.